论文部分内容阅读
目的评价尿激酶(UK)静脉溶栓治疗急性脑梗死的临床疗效及安全性。方法65例急性脑梗死患者随机双盲分为溶栓组和对照组,溶栓组32例给予尿激酶150万单位静滴,对照组33例给予安慰剂。采用欧洲卒中量表(ESS)分别评价治疗前和治疗后2小时、1天、2天、7天、14天神经功能恢复状况,Barthel指数评价90天的生活质量。结果溶栓组ESS分数升高明显,两组间有显著差异。溶栓后2小时、24小时神经功能缺损改善显著(P<0.01)。溶栓组发生脑出血1例。结论尿激酶静脉溶栓治疗急性脑梗死有效且相对安全。
Objective To evaluate the clinical efficacy and safety of intravenous thrombolysis with urokinase (UK) in the treatment of acute cerebral infarction. Methods Sixty-five patients with acute cerebral infarction were randomly divided into thrombolytic group and control group. Thrombolytic group received intravenous infusion of 1.5 million units of urokinase and control group received placebo. The European Stroke Scale (ESS) was used to assess the recovery of neurological function before treatment and 2 hours, 1 day, 2 days, 7 days and 14 days after treatment respectively. The Barthel Index was used to evaluate the quality of life at 90 days. Results The ESS score of thrombolytic group increased significantly with significant difference between the two groups. Two hours after thrombolysis, neurological deficits improved significantly at 24 hours (P <0.01). Thrombolytic group occurred cerebral hemorrhage in 1 case. Conclusions Urokinase intravenous thrombolysis is effective and relatively safe for acute cerebral infarction.